Zymeworks Completes Acquisition of Theravance Biopharma

VANCOUVER, British Columbia, Sept. 23, 2026 /CourierPR/ -- Zymeworks Inc., a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, has completed its acquisition of Theravance Biopharma. This strategic move aligns with Zymeworks’ long-term vision to build a diversified revenue-generating biotechnology company, combining innovative research and development with growing commercial and royalty-based cash flows.

The acquisition of Theravance Biopharma is a significant step in Zymeworks’ strategy to maximize value creation. Zymeworks will host a conference call with investors and the general public on September 28 at 8:30 am Eastern Time to discuss the final transaction details. The call will be available for dial-in and webcast, with the link accessible on Zymeworks’ website at ir.zymeworks.com/events-and-presentations.

Zymeworks’ portfolio includes several key assets. YUPELRI® (revefenacin), a commercialized product, is expected to contribute to the company’s revenue. Additionally, Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody, is being commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines. Pasritamig, a clinical-stage multispecific antibody, is also part of Zymeworks’ pipeline, developed using the company’s proprietary Azymetric™ platform and expertise in antibody-drug conjugates and other next-generation antibody technologies.

The acquisition of Theravance Biopharma is anticipated to bring additional value to Zymeworks. The company’s management will provide insights into the strategic benefits of this acquisition during the upcoming conference call. Zymeworks is committed to advancing its pipeline of innovative biotherapeutics, leveraging its integrated drug development expertise and strategic partnerships.

Forward-looking statements in this press release, including those related to the anticipated benefits of the acquisition and the potential for future growth, are subject to risks and uncertainties. Zymeworks believes that the acquisition will enhance its portfolio and position it for future success, but the realization of these benefits is not guaranteed. The press release notes that these forward-looking statements are made under the safe harbor provisions of the United States Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and are subject to the risks and uncertainties described in the company’s filings with the U.S. Securities and Exchange Commission.